Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pexacerfont. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 known ✓ | P34998 | 2/20 | 1.00 |
| ▸ | TACR2 | P21452 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pexacerfont SCHEMBL2929753 | 1.00 | CRHR1 (1.00) | CRHR1TACR2 | |
| Pexacerfont SCHEMBL5230356 | 1.00 | CRHR1 (1.00) | CRHR1TACR2 | |
| Pexacerfont SCHEMBL5235999 | 1.00 | CRHR1 (1.00) | CRHR1TACR2 | |
| SCHEMBL14608733 | 0.87 | CRHR1 (0.77) | CRHR1TACR2 | |
| SCHEMBL13480613 | 0.78 | TACR2 (0.63) | CRHR1TACR2 | |
| SCHEMBL21882508 | 0.77 | CRHR1 (0.63) | CRHR1TACR2 | |
| SCHEMBL5232112 | 0.76 | TACR2 (0.60) | CRHR1TACR2 | |
| SCHEMBL20628685 | 0.67 | TACR2 (0.50) | CRHR1TACR2 | |
| SCHEMBL5233264 | 0.67 | TACR2 (0.50) | CRHR1TACR2 | |
| SCHEMBL2931046 | 0.67 | CRHR1 (1.00) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4450070-A1 | CRF1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240058342-A1 | TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | NEUROCRINE BIOSCIENCES, INC. | 2024-02-22 | — | — | US | disclosed |
| US-11730739-B2 | Treatment of congenital adrenal hyperplasia | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11311544-B2 | Treatment of congenital adrenal hyperplasia | NEUROCRINE BIOSCIENCES, INC. (US) | 2022-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730739-B2 | Treatment of congenital adrenal hyperplasia | CRHR1, MC2R, CRH | CRHR1 1/4885TACR2 272/4885 |
| US-11311544-B2 | Treatment of congenital adrenal hyperplasia | CRHR1, MC2R, CRH | CRHR1 1/4885TACR2 272/4885 |
| US-20240058342-A1 | TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA | CRHR1, MC2R, CRH | CRHR1 1/4885TACR2 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.